BioCryst Pharmaceuticals BCRX
$7.22 −$0.10 (-1.37%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.10 -1.66%
Open$7.26
Prev close$7.32
Day range$7.15 – $7.39
Volume3.85M
Market cap$1.86B
P/E (TTM)–
Dividend yield–
BCRX Stock News
Headlines matching BioCryst Pharmaceuticals or the BCRX ticker, most recent first.
- Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16
- J.P. Morgan Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Raises Target Price to $13 Positive
- BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities
- BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities
- BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities
- BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities
- BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities
- RBC Capital Downgrades BioCryst Pharmaceuticals(BCRX.US) to Hold Rating, Cuts Target Price to $11 Negative
- H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32
- RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13 Negative
- Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating Positive
- Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $20 Negative
- RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating Positive
- TD Cowen Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $30
- RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $14 Positive
No comments yet — be the first to weigh in on BCRX.
Sign in to join the discussion.